Ligand Pharmaceuticals Reports 14% Revenue Growth to $51.7 Million in Q1 2026

Ligand Pharmaceuticals Incorporated reported a total revenue of $51.7 million for the first quarter of 2026, marking a 14% increase from $45.3 million in the same period last year. The growth was primarily driven by a significant rise in royalties, which surged by 56% to $43 million, largely due to increased sales of products such as Filspari, Ohtuvayre, Capvaxive, and Kyprolis. However, revenue from Captisol sales decreased by 36% to $8.7 million, attributed to the timing of customer orders, while contract revenue plummeted by 97% to $0.1 million, reflecting the absence of a regulatory milestone that had contributed to the previous year's figures.

In terms of expenses, Ligand saw a substantial reduction in total operating costs, which fell by 58% to $34.4 million compared to $81.5 million in Q1 2025. This decline was driven by a 96% decrease in research and development expenses, which dropped to $2.1 million, primarily due to the absence of a significant funding payment recognized in the prior year. General and administrative expenses increased by 11% to $20.8 million, reflecting higher employee-related costs. The company reported an operating income of $17.4 million, a notable turnaround from an operating loss of $36.2 million in the previous year.

Ligand's balance sheet as of March 31, 2026, showed total assets of $1.53 billion, a slight decrease from $1.56 billion at the end of 2025. Cash and cash equivalents decreased to $115.1 million from $174.9 million, while short-term investments increased to $664.3 million from $558.6 million. The company’s liabilities totaled $534.8 million, down from $543.4 million, with a notable increase in accounts payable and accrued liabilities. Stockholders' equity also decreased to $997.3 million from $1.02 billion, reflecting the net loss incurred during the quarter.

Looking ahead, Ligand announced plans to acquire XOMA for $39.00 per share, a transaction expected to close in the third quarter of 2026, pending regulatory approvals. This acquisition is anticipated to diversify Ligand's royalty portfolio significantly, adding over 120 assets across various therapeutic areas. Additionally, the company has terminated its TR-Beta Program with Viking Therapeutics, citing insufficient development progress. Ligand aims to leverage its regained control over the program to explore alternative strategies for advancing development in this area.

Overall, Ligand's financial performance in Q1 2026 reflects a strategic focus on enhancing its royalty-generating capabilities while managing costs effectively. The company remains committed to pursuing growth opportunities through acquisitions and partnerships, positioning itself for continued success in the biopharmaceutical sector.